Unsafe medicines remain one of the most underreported public health threats in Africa.
Globally, adverse drug reactions (ADRs) are estimated to be the 4th leading cause of death in hospitalized patients, accounting for over 10% of hospital admissions in some low- and middle-income countries (LMICs) (WHO, 2022). In Africa, pharmacovigilance systems are often weak, leading to underreporting rates as high as 94% (Uppsala Monitoring Centre, 2021).

With Nigeria’s pharmaceutical market expected to grow to $2.36 billion by 2029, the absence of robust, real-time drug safety monitoring presents a growing risk to patients, providers, and manufacturers alike.

IntraHub Technologies is addressing this urgent need through a comprehensive pharmacovigilance ecosystem tailored for the African context. Our platform, IntraVigi™, is an AI-enabled, cloud-based system that enables real-time ADR reporting via mobile, voice, WhatsApp, and offline tools. It supports MedDRA coding, E2B(R3) submissions, and automated reporting to NAFDAC and other regulatory authorities, ensuring full compliance with WHO and ICH guidelines.

Beyond the platform, we offer:

Pharmacovigilance consulting: ADR case management, risk minimization planning, and compliance audit readiness for pharmaceutical companies and CROs

Accredited training and capacity building: Self-paced e-learning, and institutional training programs to empower healthcare workers across the region

We are not just building a product — we are building the infrastructure for proactive drug safety monitoring in Africa. By combining local insight, regulatory expertise, and scalable technology, IntraHub aims to close Africa’s pharmacovigilance gap, improve patient safety outcomes, and support safe market growth across the continent.

Impact/Potential:

- Improved pharmacovigilance can lead to better public health outcomes through early detection of safety signals and timely interventions.   
- Reduced adverse drug reactions will decrease patient morbidity, mortality, and hospitalizations.   
- Enhanced public trust in the healthcare system due to a commitment to drug safety.   
- Pharmaceutical companies can benefit from reduced costs associated with product recalls and fines.   
- Improved brand reputation for pharmaceutical companies demonstrating a proactive approach to drug safety.   
